Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

Go back to Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
(NASDAQ: ARVN) Delayed: 7.64 --0 (-0%)
Previous Close $7.64    52 Week High $ 
Open $7.64    52 Week Low $ 
Day High $7.64    P/E N/A 
Day Low $7.64    EPS $ 
Volume 343       

Pfizer Inc. (NYSE: PFE) Delayed: 28.28 --0 (-0%)
Previous Close $28.28    52 Week High $37.39 
Open $28.28    52 Week Low $28.25 
Day High $28.28    P/E 17.14 
Day Low $28.28    EPS $1.65 
Volume 68,977       

Pfizer Inc. (NYSE: PFE) Delayed: 28.28 --0 (-0%)
Previous Close $28.28    52 Week High $37.39 
Open $28.28    52 Week Low $28.25 
Day High $28.28    P/E 17.14 
Day Low $28.28    EPS $1.65 
Volume 68,977